Abbott Laboratories upgraded to Buy ahead of Q2 2026 earnings on growth from Exact Sciences acquisition

Abbott Laboratories has been upgraded to Buy ahead of its Q2 2026 earnings report, following a period of share price decline exceeding 20%. The recent acquisition of Exact Sciences is expected to add a high-growth cancer diagnostics segment, targeting $3 billion in incremental sales by 2026 and supporting long-term revenue growth. The company projects 6.5–7.5% organic sales growth and adjusted EPS between $5.38 and $5.58 for 2026, despite a $0.20 EPS dilution from the acquisition. Abbott's strong balance sheet and improving core business trends underpin a recovery outlook toward previous share price highs.